CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2020 Earnings Conference Call - Final Transcript

Aug 06, 2020 • 05:30 pm ET

Previous

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Q & A
Analyst
Etzer Darout

bit about maybe where you and Astellas plan to sort of concentrate or focus sort of your energy, if you will, in terms of sort of the Bispecific landscape and where you may find indications, I guess, that are more appropriate for the technology. Thanks.

Executive
Sean A. McCarthy

Yes. Great. Hi, Etzer. Thanks for the questions. So, yes, we are actively gearing up to start an expansion cohort or a expansion cohorts of 2009 in triple-negative, both as a monotherapy and in combination with 072. I want to reiterate that we have seen single agent activity for both Probodies 072 and 2009 in triple-negative. So, we think this is an exciting experiment to do with the potential for competitive differentiation further down the road. So that study, we aim to get up and running second half.

With regards to Astellas, we haven't guided on the specific focus of the programs there in terms of tumor types. I would just say broadly speaking, that our strategy in using our Probody masking technology on CD3 Bispecifics is from the CytomX point of view is largely directed at solid tumors, where we see the need for substantial improvements because this has been a very tough area to break into for reasons a very, very narrow and compressed therapeutic window with solid tumor target. So, broadly speaking, we've developed the technology to address solid tumors. It certainly could have application in hematologic, I can't speak specifically for Astellas.

Analyst
Etzer Darout

Great. And congrats on the progress.

Executive
Sean A. McCarthy

Great. Thank you very much.

Operator
Operator

Thank you. Our next question comes from Terence Flynn of Goldman Sachs. Your line is open.

Analyst
Terence Flynn

Hi, thanks for taking the question. I was just wondering on 2029, regarding the Phase 2 program. I know you ran through, it sounds like three different tumor types were focused on there. Can you maybe just give us some insight in terms of how many patients you think would be eligible. If you look at US, EU5 and Japan for treatment here with 2029, just trying to kind of think about the potential market opportunity. Thank you.

Executive
Sean A. McCarthy

Yes. Hi, Terence. Great question. So, let me just run through the four expansions again for clarity. So, the squamous head and neck, squamous non-small cell lung, squamous esophageal and then DLBCL. The first two indications, we demonstrated confirmed partial responses in Phase 1 dose escalation. Squamous esophageal, we've shown preclinical activity in xenograft models, similarly DLBCL strong preclinical activity in that indication that's the first hematologic indications, that's one that has arisen through our discussions with our collaborator, AbbVie. They have a strong interest in hematologic malignancies, as you know.

In terms of penetration of the patient population, of the market size and the line of therapy, it's really too early to tell at this stage. We are optimistic based on the Phase 1 data. Of course, that we have a very unique active single agent against a previously undruggable target that has shown in some of the case studies that we presented